WebDoctor Encyclopedia

Ovarian

Mucinous ovarian carcinoma

Mucinous ovarian carcinoma is an uncommon ovarian cancer whose cells make mucin. It often forms a very large tumour in one ovary and is usually found at stage I, when surgery is often curative.

Medically reviewed Last reviewed October 17, 2026

What is mucinous ovarian carcinoma?

Mucinous ovarian carcinoma is an uncommon type of epithelial ovarian cancer. Its cells produce mucin, a thick, jelly-like substance similar to the mucus made by the bowel.

It accounts for only about 3-4% of ovarian cancers. It behaves very differently from the commonest type, high-grade serous carcinoma.

Mucinous ovarian carcinoma often forms a very large tumour in one ovary, sometimes more than 20 cm across. Despite its size, about 80% are found at stage I, while the cancer is still confined to the ovary, and most of these women are cured with surgery.

Many mucinous tumours found in the ovaries actually started somewhere else, most often in the appendix, bowel, stomach or pancreas. Telling the two apart is one of the most important steps in diagnosis, because the treatment is different.

When mucinous ovarian carcinoma has spread at diagnosis, it responds poorly to standard ovarian cancer chemotherapy, and the outlook is worse than for other types.

1. Key facts at a glance

Feature Details
Type of cancer Epithelial ovarian cancer producing mucin
How common About 3-4% of ovarian carcinomas
Typical age Usually younger than other ovarian cancers; median about 45-55, with some cases under 40
Typical tumour Large, one-sided, multi-cystic mass
Stage at diagnosis About 80% are stage I
Key gene changes KRAS mutations in about half to two-thirds; HER2 amplification in about 15-20%; CDKN2A and TP53 changes
Tumour markers CA19-9 and CEA often raised more than CA125
Main treatments Surgery; chemotherapy for higher-stage or infiltrative tumours
Outlook Stage I: about 90% alive at 5 years; advanced stage: poor

Mucinous ovarian tumours form a spectrum, from harmless to malignant. Carcinomas often develop from borderline tumours, and different areas of one tumour may show different stages of this process.

Tumour Behaviour
Mucinous cystadenoma Benign; removed by surgery
Mucinous borderline tumour Low malignant potential; almost always cured by surgery
Mucinous carcinoma, expansile pattern Cancer cells push outwards in a confluent sheet; lower risk of spread
Mucinous carcinoma, infiltrative pattern Cancer cells invade the surrounding tissue in small groups; higher risk of recurrence and spread
Metastatic mucinous cancer Started in the appendix, bowel, stomach, pancreas or cervix and spread to the ovaries; usually affects both ovaries

Doctors sometimes find different patterns in a single tumour: benign, borderline and malignant areas side by side. For this reason, pathologists examine many samples from a large mucinous tumour, so that a small area of invasive cancer is not missed.

Pseudomyxoma peritonei, a build-up of jelly in the abdomen, almost always comes from an appendix tumour rather than the ovary.

3. Causes and risk factors

Factor Notes
Smoking Clearly linked to mucinous ovarian tumours, unlike most other ovarian cancers
Borderline tumours Many carcinomas grow from a pre-existing mucinous borderline tumour
Teratoma A few arise in a dermoid cyst (mature teratoma)
BRCA mutations Not usually linked; mucinous carcinoma is uncommon in BRCA carriers
Pregnancy and the pill Protective effects seen for other ovarian cancers are weaker for mucinous types

4. How does it look?

4.1 Inside the body and at surgery

Feature What it looks like
Size Often very large, commonly 15-20 cm or more
Side Usually one ovary; tumours in both ovaries suggest spread from elsewhere
Surface Smooth outer surface in most primary tumours
Inside Many cysts filled with thick, sticky mucus, with solid areas
Abdomen A visibly swollen belly when the tumour is large

4.2 On scans

Test Typical findings
Pelvic ultrasound A large, multi-chambered cyst with many thin walls, sometimes with solid parts
MRI Different-looking compartments (“stained-glass” appearance) because of mucus of varying thickness
CT of chest, abdomen and pelvis Looks for spread and checks the appendix, bowel, stomach and pancreas

4.3 Under the microscope

Feature What the pathologist sees
Cells Tall cells full of mucin, resembling bowel or stomach lining
Pattern Expansile (confluent) or infiltrative (destructive) invasion
Stains Usually CK7 positive; CK20 and CDX2 variable; SATB2 usually negative, which helps exclude bowel cancer
HER2 testing Recommended, as some tumours may respond to HER2-targeted drugs

5. Symptoms

5.1 Common symptoms

Symptom Notes
Swollen or bloated tummy The most common sign, often because of a large mass
A lump in the lower abdomen Sometimes felt by the woman herself
Pelvic or abdominal pain A dull ache or pressure
Feeling full quickly The tumour presses on the stomach
Needing to pass urine often Pressure on the bladder
Constipation Pressure on the bowel
Weight gain around the waist From the size of the tumour

5.2 Sudden symptoms

Symptom Possible cause
Sudden severe pain Twisting (torsion) or rupture of the tumour
Shortness of breath Fluid in the abdomen or around the lungs in advanced disease

5.3 When to see a doctor

See a doctor if you have bloating, a swollen tummy, pelvic pain or feeling full quickly on most days for three weeks or more. These symptoms are common and usually harmless, but a blood test (CA125) and a pelvic ultrasound can quickly check the ovaries.

6. Diagnosis

Test Why it is done
Pelvic and abdominal examination Feels for a mass
Transvaginal and abdominal ultrasound First imaging test
CA125, CA19-9 and CEA Tumour markers; CA19-9 and CEA are often higher than CA125 in mucinous tumours
CT or MRI Assesses spread and looks for a primary cancer elsewhere
Colonoscopy or gastroscopy If a bowel or stomach origin is suspected
Surgery and pathology The final diagnosis is usually made after removal of the ovary; frozen section during surgery can help guide the operation
HER2 testing Identifies patients who may benefit from targeted drugs

Staging

Ovarian cancer is staged using the FIGO system.

Stage Meaning
I Confined to one or both ovaries (IA, IB) or with surface involvement or rupture (IC)
II Spread within the pelvis
III Spread to the abdominal lining or lymph nodes
IV Distant spread, such as to the liver or lungs

Primary ovarian or spread from elsewhere?

This question shapes the whole treatment plan. Doctors and pathologists look at several clues together.

Clue Suggests primary ovarian Suggests spread from elsewhere
Number of ovaries involved One Both
Tumour size Large, often over 10-13 cm Smaller
Ovarian surface Smooth Tumour on the surface
Background Borderline tumour or benign mucinous areas nearby Nodules and invasion throughout
Stains CK7 strongly positive, SATB2 negative CK20, CDX2 and SATB2 positive (bowel); other patterns for stomach or pancreas
Other tests Normal bowel and stomach examinations A tumour found in the appendix, bowel, stomach or pancreas

7. Treatment

Treatment is planned by a gynaecological oncology team. For most women the tumour is removed first, and the final pathology report then guides whether more treatment is needed.

Because many women with mucinous ovarian carcinoma are younger, fertility is often an important part of the discussion. With stage I expansile tumours, keeping the womb and the other ovary is often safe.

7.1 Surgery

Procedure Notes
Removal of the affected ovary and tube The first step; the tumour is removed intact where possible to avoid rupture
Hysterectomy and removal of the other ovary Standard for women who have completed their families
Fertility-sparing surgery Removing only one ovary is an option for young women with stage I expansile tumours
Omentectomy and peritoneal biopsies For accurate staging
Appendicectomy If the appendix looks abnormal, to exclude an appendix primary
Lymph node removal Usually not needed for expansile stage I tumours, as nodes are rarely involved; may be considered for infiltrative tumours
Debulking surgery For advanced disease, removing all visible tumour if possible

7.2 Chemotherapy and targeted treatment

The best chemotherapy for mucinous ovarian carcinoma is uncertain. An international trial comparing standard ovarian chemotherapy with a bowel-cancer regimen (mEOC/GOG 0241) closed early because too few women could be recruited, so decisions rely on smaller studies and expert opinion.

Situation Approach
Stage IA/IB, expansile Usually no chemotherapy; surveillance
Stage IC or infiltrative stage I Chemotherapy may be considered after discussion of risks and benefits
Stage II-IV Carboplatin and paclitaxel is standard; some centres use bowel-cancer regimens (oxaliplatin with capecitabine or 5-FU), though trial evidence is limited
HER2-positive HER2-targeted drugs such as trastuzumab or trastuzumab deruxtecan may be options for recurrent disease
Recurrence Further chemotherapy, surgery in selected cases, and clinical trials

Women with advanced or recurrent disease should ask about clinical trials. Because this cancer is rare, international studies are the main way new treatments are tested.

8. Side effects of treatment

Treatment Possible effects What helps
Surgery Pain, wound problems, blood clots, early menopause if both ovaries are removed Pain relief, early walking, clot-prevention injections, hormone advice
Carboplatin and paclitaxel Hair loss, numbness in hands and feet, low blood counts, tiredness Supportive medicines, dose changes
Oxaliplatin and capecitabine Cold-related nerve tingling, sore hands and feet, diarrhoea Avoiding cold drinks, creams, dose adjustment

9. Outlook

Situation Approximate 5-year survival
Stage I, expansile Over 90%
Stage I, infiltrative Somewhat lower, as recurrence is more likely
Stage II About 60-70%
Stage III-IV Poor; median survival often under 2-3 years

For most women, mucinous ovarian carcinoma is found early and cured by surgery. The picture is very different for the minority with advanced disease.

Mucinous carcinoma that has spread is less sensitive to chemotherapy than high-grade serous cancer. This is why research into gene-targeted treatments, such as drugs against HER2, is important.

10. Follow-up

Time after treatment Typical follow-up
Years 1-2 Review every 3-4 months, with tumour markers (often CA19-9 or CEA) and scans if needed
Years 3-5 Every 6 months
After 5 years Yearly or return to routine care

Women who had fertility-sparing surgery need regular scans of the remaining ovary. Removing it may be discussed once they have completed their families.

Most recurrences happen within the first two to three years. Report new bloating, pain or a change in bowel habit. Smoking cessation support, healthy eating and physical activity help recovery after surgery and chemotherapy.

11. Frequently asked questions

Question Answer
Can I still have children? Often yes, if the cancer is stage I and only one ovary is removed
Why did the doctors check my bowel? Mucinous cancers from the bowel, appendix or stomach can spread to the ovaries and look very similar
Is it inherited? Rarely. BRCA genes are not usually involved, but genetic testing may still be offered
Why is my CA125 normal? Mucinous tumours often raise CA19-9 or CEA instead
Does stopping smoking help? Yes. It is good for overall health and recovery, and smoking is a risk factor for this tumour type

12. Questions to ask your care team

  • Is my tumour definitely primary ovarian, and how was spread from the bowel or appendix ruled out?
  • Is the invasion expansile or infiltrative, and what stage is it?
  • Can I have fertility-sparing surgery?
  • Do I need chemotherapy, and which type?
  • Has my tumour been tested for HER2 and other targetable changes?
  • Which tumour marker will be used to monitor me?

Resources

  1. WHO Classification of Tumours Editorial Board (2020) Female Genital Tumours. 5th edn. Lyon: International Agency for Research on Cancer.
  2. Morice, P. et al. (2019) ‘Mucinous ovarian carcinoma’, New England Journal of Medicine, 380(13), pp. 1256-1266.
  3. Babaier, A. and Ghatage, P. (2020) ‘Mucinous cancer of the ovary: overview and current status’, Diagnostics, 10(1), p. 52.
  4. Lee, K.R. and Young, R.H. (2003) ‘The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases’, American Journal of Surgical Pathology, 27(3), pp. 281-292.
  5. Gore, M. et al. (2019) ‘An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor’, Gynecologic Oncology, 153(3), pp. 541-548.
  6. Gonzalez-Martin, A. et al. (2023) ‘Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up’, Annals of Oncology, 34(10), pp. 833-848.
  7. National Cancer Institute (2026) Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/ovarian/hp/ovarian-epithelial-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.